New Zealand markets close in 6 hours 32 minutes

Aelis Farma SA (AELIS.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
12.80-0.20 (-1.54%)
At close: 11:10AM CEST
Full screen
Previous close13.00
Open13.00
BidN/A x N/A
AskN/A x N/A
Day's range12.80 - 13.00
52-week range12.80 - 14.00
Volume161
Avg. volume300
Market cap167.75M
Beta (5Y monthly)0.12
PE ratio (TTM)N/A
EPS (TTM)-0.39
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.70
  • Business Wire

    Results of Aelis Farma Combined General Meeting of June 4, 2024

    BORDEAUX, France, June 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.

  • Business Wire

    Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures

    BORDEAUX, France, May 14, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Tuesday, June 4, 2024, at 2 p.m., at 1 rue Lafaurie de Mondabon, 33000 Bordeaux.

  • Business Wire

    Aelis Farma: Availability of the 2023 Universal Registration Document

    BORDEAUX, France, April 25, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication of its 2023 Universal Registration Document (URD) approved by the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 24, 2024, under number R.24-004.